10x Genomics (TXG) Reports Earnings Thu, Feb 13: Key Estimates and Outlook

10x Genomics (NASDAQ:TXG) will report earnings Thu, Feb 13, following market close. Last quarter, the company posted revenue of $149 million, 4.6% above expectations and 1.7% YoY down; it also beat EPS guidance. For this quarter, analysts expect revenue to decline 3.5% YoY to $159.2 million, versus the 10.3% drop in Q4 2024. The adjusted loss is forecast at -$0.04 per share. Context: The life sciences tools & services sector underperformed last month (-3.7%) amid economic uncertainty and potential tariff/tax changes. 10x Genomics is down 4.5% over the same period, trading at $19.16 vs an average analyst price target of $18.08. Peers: Illumina +5% YoY and Medpace +32% YoY in Q4.